Amnis Therapeutics Ltd.

amnis.life (under construction)

Formerly ITGI

High-Tech Company

Ceased to Operate Q1/2016

TECH VERTICALS

Cardiology, Healthtech, Life Sciences, Medical Devices, MedTech, Stents

General Data

Sector	Medical Devices
Company Stage:	Initial Revenues
Established	2003
Number of Employees	10
Reg. Number:	abCDe

DESCRIPTION

Amnis Therapeutics is an Israeli bio-med engineering company, specializes in developing, manufacturing and marketing of lifesaving endovascular technologies for emergency situations. The company’s portfolio and future pipeline of products focus on biocompatible minimally invasive devices addressing unmet needs in interventional cardiology and neuroradiology.
The company has developed patent-protected technology to cover stents with biological tissues for emergency vessel reconstruction such as brain and heart aneurysms, ruptures in arteries and more. The company's latest development is a unique device for the extraction of blood clots from the brain in stroke patients.
Their mission is to provide the medical community with innovative, high-performance devices that offer a reliable, proven solution for numerous endovascular indications.

TECHNOLOGY

The company focuses on current technologies and applications that improve the standard of care for patients around the world in the fields of interventional Cardiology and Interventional Neuro-Radiology for the application in Coronary and neurological aneurysms, treatment of Fistulas, Saphenous Vein Graft occlusion (SVG Disease) and vascular perforations. Studies conducted prove thatAmnis Therapeutics's propriety technology can address these clinical problems in a safe
and effective manner.

Amnis Therapeutics's currently main area of development is:

· Neurological applications of the Heterologous tissue partially covered stent.

· Coronary application of the Heterologous tissue 100% covered stent.

Products and Phases

Product	Phase
Aneugraft(C)	FDA Approved CE Approved
The Aneugraft ® heterologous covered stent is intended to treat coronary indication in tortuous vessels. Due to its superb delivery system, it can perform in challenging anatomy. The product is approved to use in coronary indications and is planned to be used also for the treatment of cerebral aneurysms.
Golden Retriever	Phase II
The Golden retriever is the future of fast and efficient blood clot retrieval. The Unique design is the thinnest on the market today, navigating like a wire to the clot, it retrieves the clot exerting minimal radial force on the vessel wall.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Interventional cardiologists, Interventional neuroradiologists, Endovascular operators.

	BUSINESS MODEL
	B2B2C

COMPETITORS

InspireMD

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Accounting Firm

REMARKS

Date	Remark
01/01/2007	Merged with Design & Performance Ltd. of Cyprus.

CONTACT INFO

Expand / Collapse All

Main Address: Or Akiva, Israel

Address	22 Hailan St.
POB	146
City	Or Akiva
Country	Israel
Zip	3060000

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Zvi Boms	Founder
Mr. Noam Shamay	Inventor

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Founder, ITGI
abC Defghij	Board Member	Advocate
abC Defghij	Board Member	The Director of Interventional Cardiology at the Hadassah-Hebrew University Medical Center
abC Defghij	External Director	CFO, Fiberzone Networks
abC Defghij	Board Member	CEO, Acum
abC Defghij	External Director	Senior Member of Management, YES
abC Defghij	Advisory Board Member	Head of the Interventional Radiology Department at Military-Medicine Academy named after S.M. Kirov, St. Petersburg
abC Defghij	Advisory Board Member	Professor and Head, Chief Physician Department of Neuroradiology at Alfred Krup Hospital, Essen Germany
abC Defghij	Advisory Board Member	Professor of Radiology at the University of Lyon, France
abC Defghij	Advisory Board Member	Director of Heart Institute, the Hadassah Medical Center

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Jul. 05, 2007	IPO	TASE	abCDe	abCDe	12/2017: Delisted and became private.

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Aug. 25, 2009

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

First Round

Mar. 26, 2007

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Investment Company	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe

Seed

Jan. 16, 2004

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Last Updated:	abCDe
IVC Number:	abCDe